Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
147 Results for "
Diffuse Large B Cell Lymphoma
" in MedChemExpress (MCE) Product Catalog:
Products (147)
147 Results for "Diffuse Large B Cell Lymphoma" in MCE Product Catalog:
Cat. No.: HY-19916
CAS No.: 1263384-43-5
Synonyms: BAL-101553
Research Areas:
Lisavanbulin (BAL-101553) is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin is a BBB-penetrant and orally active antitumor agent, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin is also a spindle assembly checkpoint activator. Lisavanbulin induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma .
Cat. No.: HY-122829
CAS No.: 2257479-54-0
BCL6 PROTAC 1 is a selective B-cell lymphoma 6 (BCL6) PROTAC. BCL6 PROTAC 1 inhibits BCL6 cell reporter with an IC50 value of 8.8 µM. BCL6 PROTAC 1 significantly degrades BCL6 in diffuse large B-cell lymphoma (DLBCL) cell lines. BCL6 PROTAC 1 can be used in tumor related research .
Voruciclib hydrochloride is an orally active and selective CDK inhibitor with Ki values of 0.626 nM-9.1 nM. Voruciclib hydrochloride potently blocks CDK9, the transcriptional regulator of MCL-1. Voruciclib hydrochloride represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL) .
Cat. No.: HY-163295
CAS No.: 2377645-56-0
Target:
Research Areas:
PROTAC BTK Degrader-16 is a BTK PROTAC degrader with a DC50 of 0.0006 nM in TMD8 cells. PROTAC BTK Degrader-16 recruits E3 ligase CRBN to tag BTK for degradation, leading to loss of BTK signaling. PROTAC BTK Degrader-16 induces degradation of BTK, leading to inhibition of cell growth in ABC-DLBCL cells. PROTAC BTK Degrader-16 can be used for the research of activated b-cell-like diffuse large b-cell lymphoma (ABC-DLBCL) .
Cat. No.: HY-P99501
CAS No.: 2251143-19-6
Synonyms: HS006
IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma .
BCL6-IN-6 is a potent inhibitor of transcriptional repressor B-cell lymphoma 6 (BCL6). BCL6-IN-6 significantly blocks the interaction of BCL6 with its corepressors and reactivates BCL6 target genes in a dose-dependent manner. BCL6-IN-6 has the potential for the research of diffuse large B-cell lymphoma (DLBCL) .
Cat. No.: HY-161989
CAS No.: 3105664-95-4
DZ-837 is a BCL6 PROTAC degrader with a DC50 of 557.7 nM. DZ-837 induces BCL6 ubiquitination and degradation in a CRBN-dependent manner via the ubiquitin-proteasome system. DZ-837 activates CDKN1A and CDKN1B, the downstream genes of BCL6. DZ-837 upregulates p21 and p27 proteins . DZ-837 inhibits tumor growth in a diffuse large B-cell lymphoma xenograft mouse model. DZ-837 exerts synergistic antiproliferative effects when combined with Ibrutinib (HY-10997). DZ-837 can be used in studies related to diffuse large B-cell lymphoma .
Cat. No.: HY-162651
CAS No.: 3081180-48-2
Target:
Research Areas:
PROTAC BRD9 Degrader-8 is a selective, orally active BRD9 PROTAC degrader with a DC50 of 16 pM.\nPROTAC BRD9 Degrader-8 induces cell cycle arrest at the G1 phase and promotes apoptosis. PROTAC BRD9 Degrader-8 can be used for research on acute myeloid leukemia and diffuse large B-cell lymphoma .
Cat. No.: HY-150109A
CAS No.: 1929583-17-4
Synonyms: Purinostat
Target:
Research Areas:
Puzerinostat (Purinostat) is a highly selective class I/IIb histone deacetylase (HDAC) inhibitor, with IC50 values of 0.81 nM, 1.4 nM, 1.7 nM, 3.8 nM, 11.5 nM, and 1.1 nM against HDAC1, HDAC2, HDAC3, HDAC8, HDAC6, and HDAC10, respectively. Puzerinostat enhances glutamine metabolism by upregulating GLS1. Puzerinostat induces cell Apoptosis and downregulates the expression of BCR-ABL and c-MYC. Puzerinostat delays the progression of Ph + B-cell acute lymphoblastic leukemia and prolongs the survival of relevant mouse models. Puzerinostat regulates the immune microenvironment. Puzerinostat can be used in research related to chronic myeloid leukemia, Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia, relapsed/refractory multiple myeloma, relapsed/refractory lymphoma, diffuse large B-cell lymphoma, and double-expression lymphoma .
Cat. No.: HY-19916A
CAS No.: 1387574-54-0
Synonyms: BAL-101553 dihydrochloride
Research Areas:
Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin dihydrochloride exhibits antitumor activity, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin dihydrochloride has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin dihydrochloride is also a spindle assembly checkpoint activator. Lisavanbulin dihydrochloride induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin dihydrochloride can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma .
Cat. No.: HY-177755
CAS No.: 2230406-52-5
Target:
Research Areas:
BCL6-IN-10 is a molecular glue inhibitor targeting the BCL6 BTB domain with an IC50 of 4 nM. BCL6-IN-10 blocks the interaction between BCL6 and transcriptional co-repressors, and induces partial degradation of BCL6 via the ubiquitin-proteasome pathway, thereby de-repressing BCL6 target genes and inhibiting cancer cell proliferation. BCL6-IN-10 can be used in the research of diffuse large B-cell lymphoma .
Cat. No.: HY-178803
PROTAC BCL6 Degrader-2 is an orally active, selective BCL6 PROTAC degrader (DC50: 0.45 nM in HEK293T cells). PROTAC BCL6 Degrader-2 promotes ubiquitination and degradation of BCL6. It exhibits anticancer activity against BCL6-dependent diffuse large B-cell lymphoma. PROTAC BCL6 Degrader-2 can be used for the research of diffuse large B-cell lymphoma .
Cat. No.: HY-148631
CAS No.: 2728727-91-9
Target:
Research Areas:
GSK137 is an orally active, potent and selective B-cell lymphoma 6 (BCL6) inhibitor. GSK137 blocks the interaction between BCL6 and corepressors (e.g., SMRT), reducing the number of germinal center B cells. GSK137 is promising for research of autoimmune diseases such as systemic lupus erythematosus (SLE) and B-cell-related tumors such as diffuse large B-cell lymphoma .
Cat. No.: HY-P991345
Synonyms: AMP-514
Target:
Research Areas:
Cat. No.: HY-177750
CAS No.: 2417647-40-4
Research Areas:
TD-522 is a potent and selective molecular glue GSPT1 degrader, with a DC50 of 0.269 nM. TD-522 exhibits strong anti-proliferative effects and induces apoptosis in acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL) cells. TD-522 suppresses tumor growth in a TMD-8 xenograft model. TD-522 can be used for AML and DLBCL research .
Cat. No.: HY-153820
CAS No.: 2086300-61-8
Target:
Research Areas:
PROTAC BRD4 Degrader-20 (Compound 195) is a PROTAC degrader that targets BRD4 for degradation by recruiting VHL. PROTAC BRD4 Degrader-20 is applicable to the research of diffuse large B-cell lymphoma .
Cat. No.: HY-177756
CAS No.: 2230406-60-5
BCL6-IN-11 is a potent inhibitor of the BCL6 BTB domain and a partial degrader of BCL6. BCL6-IN-11 inhibits the interaction between the BCL6 BTB domain and BCOR with an IC50 of 6 nM. BCL6-IN-11 can be used for research related to BCL6 degradation in diffuse large B-cell lymphoma (DLBCL) .
Cat. No.: HY-156745
CAS No.: 3036944-98-3
PROTAC DDa-1 is a multi-targeted DCAF1-recruiting tyrosine kinase PROTAC degrader. PROTAC DDa-1 mediates the degradation of TNK2, CSK, LIMK2, TEC, and BTK, with a DC50 of 90 nM for BTK. PROTAC DDa-1 reduces the viability of BTK-dependent diffuse large B-cell lymphoma cells. PROTAC DDa-1 can be used for the research of diffuse large B-cell lymphoma .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
